Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2002 1
2006 2
2010 4
2012 1
2013 1
2014 1
2015 1
2018 1
2019 2
2020 1
2021 2
2023 1

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
Perrot I, Michaud HA, Giraudon-Paoli M, Augier S, Docquier A, Gros L, Courtois R, Déjou C, Jecko D, Becquart O, Rispaud-Blanc H, Gauthier L, Rossi B, Chanteux S, Gourdin N, Amigues B, Roussel A, Bensussan A, Eliaou JF, Bastid J, Romagné F, Morel Y, Narni-Mancinelli E, Vivier E, Paturel C, Bonnefoy N. Perrot I, et al. Among authors: paturel c. Cell Rep. 2019 May 21;27(8):2411-2425.e9. doi: 10.1016/j.celrep.2019.04.091. Cell Rep. 2019. PMID: 31116985 Free article.
Population Pharmacokinetics of Monalizumab in Patients With Advanced Solid Tumors.
Hwang M, Fan C, Yue MS, Zhou D, Paturel C, Andre P, Cheng LY, Mitchell P, Kourtesis P, Ruscica D, Das M, Morsli N, Ren S, Gibbs M, Phipps A, Song X. Hwang M, et al. Among authors: paturel c. J Clin Pharmacol. 2023 Jul;63(7):817-829. doi: 10.1002/jcph.2220. Epub 2023 Apr 10. J Clin Pharmacol. 2023. PMID: 36852723
Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control.
Bléry M, Mrabet-Kraiem M, Morel A, Lhospice F, Bregeon D, Bonnafous C, Gauthier L, Rossi B, Remark R, Cornen S, Anceriz N, Viaud N, Trichard S, Carpentier S, Joulin-Giet A, Grondin G, Liptakova V, Kim Y, Daniel L, Haffner A, Macagno N, Pouyet L, Perrot I, Paturel C, Morel Y, Steinle A, Romagné F, Narni-Mancinelli E, Vivier E. Bléry M, et al. Among authors: paturel c. Open Res Eur. 2021 Oct 27;1:107. doi: 10.12688/openreseurope.13314.2. eCollection 2021. Open Res Eur. 2021. PMID: 35967081 Free PMC article.
The toll-like receptor agonist imiquimod is active against prions.
Oumata N, Nguyen PH, Beringue V, Soubigou F, Pang Y, Desban N, Massacrier C, Morel Y, Paturel C, Contesse MA, Bouaziz S, Sanyal S, Galons H, Blondel M, Voisset C. Oumata N, et al. Among authors: paturel c. PLoS One. 2013 Aug 16;8(8):e72112. doi: 10.1371/journal.pone.0072112. eCollection 2013. PLoS One. 2013. PMID: 23977222 Free PMC article.
A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies.
Vey N, Karlin L, Sadot-Lebouvier S, Broussais F, Berton-Rigaud D, Rey J, Charbonnier A, Marie D, André P, Paturel C, Zerbib R, Bennouna J, Salles G, Gonçalves A. Vey N, et al. Among authors: paturel c. Oncotarget. 2018 Apr 3;9(25):17675-17688. doi: 10.18632/oncotarget.24832. eCollection 2018 Apr 3. Oncotarget. 2018. PMID: 29707140 Free PMC article.
TLR3 and Rig-like receptor on myeloid dendritic cells and Rig-like receptor on human NK cells are both mandatory for production of IFN-gamma in response to double-stranded RNA.
Perrot I, Deauvieau F, Massacrier C, Hughes N, Garrone P, Durand I, Demaria O, Viaud N, Gauthier L, Blery M, Bonnefoy-Berard N, Morel Y, Tschopp J, Alexopoulou L, Trinchieri G, Paturel C, Caux C. Perrot I, et al. Among authors: paturel c. J Immunol. 2010 Aug 15;185(4):2080-8. doi: 10.4049/jimmunol.1000532. Epub 2010 Jul 16. J Immunol. 2010. PMID: 20639488 Free PMC article.
19 results